Results 1 to 10 of about 188,223 (344)

Real-World Evidence Assessing the Safety of Administering Intravenous Rituximab Biosimilar in the First Cycle and Subcutaneous Rituximab in Subsequent Cycles in B-Cell Lymphoma Patients [PDF]

Pharmacy
Background: Biosimilar versions of rituximab have similar safety and efficacy as the reference product across all indications based on the extrapolation principle. Our organization replaced intravenous (IV) rituximab (Mabthera) with IV rituximab (Truxima-
Tamather Almandeel, Mansoor Ahmed Khan, Ashwag Algethami, Mashael S. Alaboud, Munirah A. Alkathiri, Mohammed Aseeri, Ahmed Absi, Mubarak Almansour, Abdullah Alotaibi   +8 more
doaj   +2 more sources

Case series of low dose rituximab for membranous nephropathy; a single centre experience [PDF]

Journal of Nephropathology, 2023
Introduction: Rituximab is the recent treatment of choice for primary membranous nephropathy However, dose of rituximab mentioned in literature is high and not economical in middle income countries.
Gerry George Mathew, Jayaprakash Varadharajan, Sreedhar Sailapathy   +2 more
doaj   +1 more source

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy

Frontiers in Immunology, 2021
Primary membranous nephropathy (pMN) is an autoimmune kidney disease and a common cause of nephrotic syndrome in adults. Rituximab is becoming a first line therapy for patients with persistent nephrotic syndrome with proven safety and efficacy, achieving
Maxime Teisseyre, Maxime Teisseyre, Marion Cremoni, Sonia Boyer-Suavet, Sonia Boyer-Suavet, Sonia Boyer-Suavet, Thomas Crepin, Sylvia Benzaken, Kévin Zorzi, Vincent Esnault, Vesna Brglez, Vesna Brglez, Barbara Seitz-Polski, Barbara Seitz-Polski, Barbara Seitz-Polski, Barbara Seitz-Polski   +15 more
doaj   +1 more source

Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients

Frontiers in Immunology, 2023
BackgroundBy depleting circulating B lymphocytes, rituximab time-dependently suppresses coronavirus disease 2019 (COVID-19) vaccines’ humoral immunogenicity for a prolonged period.
Chutima Seree-aphinan, Yanisa Ratanapokasatit, Poonkiat Suchonwanit, Ploysyne Rattanakaemakorn, Pichaya O-Charoen, Prapaporn Pisitkun, Thanitta Suangtamai, Chavachol Setthaudom, Sonphet Chirasuthat, Kumutnart Chanprapaph   +9 more
doaj   +1 more source

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab

Frontiers in Immunology, 2020
Membranous Nephropathy (MN) is an autoimmune disease associated with antibodies against podocyte proteins: M-type phospholipase A2 receptor (PLA2R1) or thrombospondin type-1 domain-containing 7A (THSD7A) in 70 and 3% of patients, respectively.
Sonia Boyer-Suavet, Sonia Boyer-Suavet, Marine Andreani, Maël Lateb, Benjamin Savenkoff, Vesna Brglez, Sylvia Benzaken, Ghislaine Bernard, Patrick H. Nachman, Vincent Esnault, Vincent Esnault, Barbara Seitz-Polski, Barbara Seitz-Polski, Barbara Seitz-Polski   +13 more
doaj   +1 more source

Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions. [PDF]

, 2020
ObjectiveTo determine the transfer of rituximab, an anti-CD20 monoclonal antibody widely used for neurologic conditions, into mature breast milk.MethodsBreast milk samples were collected from 9 women with MS who received rituximab 500 or 1,000 mg ...
Anderson, Annika, Bevan, Carolyn, Bove, Riley, Hale, Thomas W, Krysko, Kristen M, LaHue, Sara C, Marcus, Jacqueline, Riley, Claire S, Rowles, William, Rutatangwa, Alice, Schubert, Ryan D   +10 more
core   +1 more source

Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma

Journal of Hematology & Oncology, 2022
Inevitable relapses remain as the major therapeutic challenge in patients with mantle cell lymphoma (MCL) despite FDA approval of multiple targeted therapies and immunotherapies.
Vivian Changying Jiang, Yang Liu, Alexa Jordan, Angela Leeming, Joseph McIntosh, Shengjian Huang, Rongjia Zhang, Qingsong Cai, Zhihong Chen, Yijing Li, Yuxuan Che, Lei Nie, Ingrid Karlsson, Linda Mårtensson, Mathilda Kovacek, Ingrid Teige, Björn Frendéus, Michael Wang   +17 more
doaj   +1 more source

Is it the time to offer rituximab as a cost-benefit treatment for immunoglobulin A nephropathy? A short-review to current concepts [PDF]

Journal of Nephropathology, 2018
Context: IgA nephropathy (IgAN) as an autoimmune disease is the most common cause of glomerulonephritis worldwide. Rituximab effectively depletes B cells and reduces serum levels of IgA1 antibodies.
Mohammad-Reza Tamadon, Jamileh Moghimi, Hamed Rezaei   +2 more
doaj   +1 more source

Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E [PDF]

, 2020
Hepatitis E virus (HEV) infection is an emerging disease in industrialized countries which is usually characterized by a self-limited course. However, there is an increased risk of HEV persistence in immunocompromised risk populations, comprising ...
Biedermann, Paula, Bock, Claus-Thomas, Choi, Mira, Hanitsch, Leif Gunnar, Hofmann, Jörg, Mueller, Tobias, Schulz, Marten, Tacke, Frank   +7 more
core   +1 more source

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study

Haematologica, 2018
MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia.
Anne-Sophie Michallet, Melih Aktan, Wolfgang Hiddemann, Osman Ilhan, Peter Johansson, Kamel Laribi, Balkis Meddeb, Carol Moreno, João Raposo, Anna Schuh, Ali Ünal, Tom Widenius, Alf Bernhardt, Kerstin Kellershohn, Dimitri Messeri, Stuart Osborne, Véronique Leblond   +16 more
doaj   +1 more source